Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Non-Current Assets (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Non-Current Assets for 13 consecutive years, with $6.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 22.37% to $6.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $27.4 million, a 16.41% decrease, with the full-year FY2025 number at $6.1 million, down 22.37% from a year prior.
  • Non-Current Assets was $6.1 million for Q4 2025 at Ekso Bionics Holdings, down from $6.9 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $9.9 million in Q4 2022 to a low of $1.1 million in Q1 2022.
  • A 5-year average of $5.9 million and a median of $7.2 million in 2025 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: tumbled 41.07% in 2022, then soared 749.6% in 2023.
  • Ekso Bionics Holdings' Non-Current Assets stood at $1.4 million in 2021, then skyrocketed by 619.62% to $9.9 million in 2022, then dropped by 11.72% to $8.7 million in 2023, then decreased by 10.34% to $7.8 million in 2024, then decreased by 22.37% to $6.1 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Non-Current Assets are $6.1 million (Q4 2025), $6.9 million (Q3 2025), and $7.2 million (Q2 2025).